Welcome to our dedicated page for Sight Sciences SEC filings (Ticker: SGHT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sight Sciences, Inc. (Nasdaq: SGHT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As an eyecare technology company focused on interventional glaucoma and dry eye devices, Sight Sciences uses SEC reports to communicate financial results, capital arrangements, and key corporate developments.
Investors can review Form 8-K filings where the company reports quarterly and year-to-date financial highlights, raises or updates revenue and adjusted operating expense guidance, and describes restructuring plans intended to reduce operating expenses and improve cost efficiencies. Other 8-Ks detail amendments to the company’s senior secured term loan facility with Hercules Capital, including changes to the interest-only period and tranche availability.
Filings also disclose material corporate events such as workforce reductions, executive transitions, and board changes. For example, the company has reported promotions of senior executives, entry into amended and restated employment agreements, and the resignation of directors, along with related compensation and severance terms.
These SEC documents complement the company’s press releases on clinical and reimbursement milestones for its OMNI® Surgical System, SION® Surgical System, and TearCare® System. On Stock Titan, users can access real-time updates from EDGAR and use AI-powered summaries to quickly understand the main points of lengthy filings, including quarterly (10-Q) and annual (10-K) reports when available, as well as Form 4 insider transaction reports.
AI-generated overviews help explain complex sections of Sight Sciences’ filings in plain language, highlight changes in guidance or capital structure, and point out disclosures that may be relevant to the company’s Surgical Glaucoma and Dry Eye segments. This allows readers to navigate detailed regulatory documents more efficiently while focusing on the aspects of SGHT’s business that matter most to them.
A shareholder has filed a Form 144 notice to sell SGHT common stock. The notice covers a proposed sale of 2,616 shares of common stock through Fidelity Brokerage Services LLC on or about 01/16/2026 on the NASDAQ market, with an aggregate market value of 17,310.86. The issuer has 52,871,731 shares of this class outstanding.
The 2,616 shares to be sold were acquired on 01/15/2026 via restricted stock vesting from the issuer as compensation. The person named, James Rodberg, has also sold common shares of the same issuer during the past three months, including 2,518 shares on 12/02/2025 for gross proceeds of 20,782.06, 4,405 shares on 01/05/2026 for 34,460.31, and 594 shares on 01/06/2026 for 4,444.07.
A shareholder of SGHT filed a Rule 144 notice to sell 4,836 shares of common stock, with an aggregate market value of $32,001.26, through Fidelity Brokerage Services on the NASDAQ around 01/16/2026. The filing indicates there were 52,871,731 common shares outstanding at the time this notice was prepared, which is a separate baseline figure.
The 4,836 shares were acquired on 01/15/2026 via restricted stock vesting from the issuer as compensation, with payment also dated 01/15/2026. Over the prior three months, the same seller, David Y. Badawi, reported additional common stock sales of 2,914 shares for $21,654.23, 3,051 shares for $23,867.97, and 3,695 shares for $27,644.51. By signing the notice, the seller represents that he is not aware of any undisclosed material adverse information about the issuer’s operations.
Sight Sciences (SGHT) shareholder Paul Badawi has filed a Form 144 notice indicating an intent to sell 22,362 shares of common stock through Fidelity Brokerage Services on or about 01/16/2026 on NASDAQ, with an aggregate market value of $147,976.06 at the time of the notice. These shares were acquired on 01/15/2026 via restricted stock vesting from the issuer as compensation. The notice also reports that during the past three months, Badawi sold 25,356 common shares on 01/02/2026 for gross proceeds of $188,422.97 and 11,870 common shares on 01/06/2026 for gross proceeds of $88,806.59. Shares of common stock outstanding were 52,871,731 as of the filing, providing context for the scale of these transactions.
Sight Sciences insider transaction: A notice has been filed to sell 6,308 shares of common stock of Sight Sciences through Fidelity Brokerage Services LLC on or about 01/16/2026, with the shares listed on NASDAQ. The shares relate to restricted stock that vested on 01/15/2026, acquired from the issuer as compensation.
As context, the notice reports 52,871,731 shares of common stock outstanding. It also lists prior sales during the past three months by Jeremy Hayden, including 3,150 shares sold on 11/12/2025 for gross proceeds of 25,227.78, 44,850 shares sold on 11/25/2025 for 362,596.77, 9,385 shares sold on 01/05/2026 for 73,418.85, and 1,785 shares sold on 01/06/2026 for 13,354.66.
A shareholder filed a Rule 144 notice to sell 9,748 common shares, with an aggregate market value of $64,141.84, through Fidelity Brokerage Services on the NASDAQ market. The shares relate to stock options that were granted on January 9, 2020 and May 11, 2020 and were acquired and paid for in cash on January 16, 2026.
Over the prior three months, the same seller, Erica Rogers, reported additional common stock sales, including 20,000 shares for $172,804.00 on December 29, 2025 and 20,000 shares for $132,034.00 on January 15, 2026, along with two smaller transactions. The filer certifies they are not aware of undisclosed material adverse information about the issuer’s current or prospective operations.
A shareholder filed a Form 144 notice to sell 20,000 shares of common stock through Fidelity Brokerage Services LLC on NASDAQ, with an aggregate market value of 132,034.24.
The filing states that 52,871,731 shares of this class were outstanding and that the planned sale is expected around 01/15/2026.
The 20,000 shares come from stock options granted on 01/09/2020 and 05/11/2020, each for 10,000 shares, acquired and paid for in cash on 01/15/2026. Over the prior three months, Erica Rogers sold additional blocks of common stock totaling 40,252 shares, with gross proceeds of 172,804.00, 84,223.26, and 73,781.00.
Sight Sciences, Inc. filed a current report to let investors know it has released preliminary, unaudited financial results. On January 13, 2026, the company issued a press release with selected results for the fourth quarter and full year ended December 31, 2025. That press release is included as Exhibit 99.1 to this Form 8-K under the section covering results of operations and financial condition. The company states that this information, including the exhibit, is being furnished rather than filed, which limits how it is treated under securities law and how it may be incorporated into other SEC filings.
SGHT filed a notice under Rule 144 for a planned sale of 10,000 shares of common stock through Fidelity Brokerage Services LLC on 01/12/2026, listed with an aggregate market value of 73,781.43 and referencing 52,871,731 shares outstanding and NASDAQ as the exchange.
The shares to be sold were acquired on 01/12/2026 via an option originally granted on 05/11/2020, with cash as the form of payment. The notice lists prior sales for the same account holder, Erica Rogers, including 20,000 common shares sold on 12/29/2025 for gross proceeds of 172,804.00 and 10,252 common shares sold on 12/30/2025 for gross proceeds of 84,223.26. By signing, the seller represents that they are not aware of any undisclosed material adverse information about the issuer’s operations.
Sight Sciences, Inc. insider activity: President, CEO, director and 10% owner Paul Badawi reported two sales of the company’s common stock. On January 2, 2026, he sold 25,356 shares at a weighted average price of $7.43 per share, and on January 6, 2026, he sold 11,870 shares at a weighted average price of $7.48 per share.
According to the footnotes, the January 2 sale reflects shares sold to cover his tax liability arising from the vesting of restricted stock units. Both trades were executed in multiple transactions within disclosed price ranges. After these transactions, Badawi beneficially owned 5,925,276 shares of Sight Sciences common stock directly.
Sight Sciences Chief Operating Officer Alison Bauerlein reported two open-market sales of company common stock. On January 5, 2026, she sold 10,896 shares at a weighted average price of $7.82 per share, and on January 6, 2026, she sold 9,647 shares at a weighted average price of $7.48 per share.
According to the footnotes, these sales were made to cover her tax liability arising from the vesting of restricted stock units, meaning they were linked to equity compensation rather than a discretionary reduction in holdings. After these transactions, she beneficially owned 599,983 shares of Sight Sciences common stock directly.